Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...
However, they also respond more quickly to treatment, according to Cleveland Clinic. The most common type is diffuse ...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...
Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...
This is a CAR-T therapy for adults diagnosed with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell ...
"With almost all provinces onboard, urgent medicines can now be more accessible to patients with diseases such as R/R DLBCL across the country," said Antonella Rizza, CEO, Lymphoma Canada.
The study systematically characterized RILD using bronchoalveolar lavage and high-resolution CT in 321 patients, mostly with ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology ...
Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.
Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, ...